Analysts expect Integra Lifesciences Holdings Corp (NASDAQ:IART) to announce $380.94 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Integra Lifesciences’ earnings. The highest sales estimate is $381.90 million and the lowest is $379.80 million. Integra Lifesciences posted sales of $368.60 million during the same quarter last year, which suggests a positive year over year growth rate of 3.3%. The company is scheduled to issue its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Integra Lifesciences will report full-year sales of $1.47 billion for the current year. For the next year, analysts expect that the business will post sales of $1.54 billion, with estimates ranging from $1.52 billion to $1.55 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.59. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The firm had revenue of $365.85 million for the quarter, compared to analysts’ expectations of $367.89 million. During the same period in the prior year, the business posted $0.45 earnings per share. The business’s revenue was up 31.2% compared to the same quarter last year.
In other news, Director Barbara B. Hill purchased 3,705 shares of the business’s stock in a transaction dated Monday, November 5th. The shares were acquired at an average price of $53.90 per share, with a total value of $199,699.50. Following the completion of the purchase, the director now directly owns 63,381 shares of the company’s stock, valued at approximately $3,416,235.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Richard E. Caruso sold 46,676 shares of the company’s stock in a transaction on Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total value of $2,949,456.44. Following the transaction, the insider now directly owns 134,134 shares in the company, valued at approximately $8,475,927.46. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of IART. LPL Financial LLC lifted its stake in shares of Integra Lifesciences by 28.6% during the first quarter. LPL Financial LLC now owns 6,840 shares of the life sciences company’s stock valued at $376,000 after acquiring an additional 1,523 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Integra Lifesciences by 2.1% during the first quarter. Principal Financial Group Inc. now owns 494,735 shares of the life sciences company’s stock valued at $27,379,000 after acquiring an additional 10,388 shares during the period. Bank of Montreal Can lifted its stake in shares of Integra Lifesciences by 55.8% during the second quarter. Bank of Montreal Can now owns 16,018 shares of the life sciences company’s stock valued at $1,031,000 after acquiring an additional 5,739 shares during the period. Retirement Systems of Alabama acquired a new position in shares of Integra Lifesciences during the second quarter valued at $5,884,000. Finally, World Asset Management Inc acquired a new position in shares of Integra Lifesciences during the second quarter valued at $261,000. 85.55% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:IART traded up $0.17 during trading hours on Friday, reaching $52.96. The company had a trading volume of 334,420 shares, compared to its average volume of 754,281. Integra Lifesciences has a one year low of $45.96 and a one year high of $67.50. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of 27.30, a price-to-earnings-growth ratio of 1.64 and a beta of 0.76. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.20 and a quick ratio of 2.08.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Further Reading: How To Calculate Debt-to-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.